IPH5201 (CD39 mAb): initiation of Phase 2 clinical trial MATISSE
24 February 2023First patient dosed in phase 2 MATISSE trial of IPH5201
26 June 2023
Jeremy BASTID, CEO of OREGA Biotech, will attend the upcoming AACR annual meeting to be held on April 14 – 19, 2023 in Orlando, Florida.
